New antibiotics for antibiotic-resistant bacteria
William Stubbings and Harald Labischinski*

Address: MerLion Pharmaceuticals GmbH, Robert-Röessle-Str-10, D-13125 Berlin, Germany

* Corresponding author: Harald Labischinski (labischinski@merlionpharma.de)

F1000 Biology Reports 2009, 1:40 (doi:10.3410/B1-40)

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes.

The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Biology/content/1/40

Abstract
The need for new antibiotics to effectively treat antibiotic-resistant infections remains unfulfilled. Despite the well-publicised concern over this issue, only two novel antibiotic classes have been introduced in the past 20 years alongside several new agents of existing classes. Accordingly, the current antibiotic armoury remains inadequate to meet the challenges posed by resistance today. More worryingly, there are very few new agents being developed that can be expected to replace existing antibiotics that succumb to the rising tide of resistance.

Introduction and context
Antibiotic resistance among pathogenic bacteria is a well-documented phenomenon that has severe consequences for the treatment of infections in the hospital setting and increasingly in the community. The Infectious Diseases Society of America recently published a hit list of bacterial pathogens [1] whose antibiotic resistance severely impacts the ability to treat infections in the US hospital setting. This list is comprised of Staphylococcus aureus, Enterococcus faecium, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Enterobacter spp. In addition, the emergence of community-acquired methicillin-resistant S. aureus (MRSA) [2] and extensively drug-resistant (XDR) Mycobacterium tuberculosis [3] demonstrates that problematic resistance is not limited to the confines of the hospital. This article attempts to evaluate recent therapeutic options available for the treatment of resistant infections and the progress being made in terms of discovery and development of the next generation of antibacterials that will be relied upon for treating such infections in the next decade.

Major recent advances
Current antibiotics
The emergence of MRSA and vancomycin-resistant enterococci (VRE) highlighted an urgent need for novel antibiotics that are not affected by existing mechanisms of resistance. In this decade, two antibacterials that belong to new classes - linezolid (an oxazolidinone) and daptomycin (a lipopeptide) - were approved and have offered new options for the treatment of, for example, complicated skin and skin structure infections (cSSSIs) caused by resistant Gram-positive pathogens.

In addition, there are a few new agents that soon could be introduced for the treatment of Gram-positive infections in the hospital. The glycopeptide telavancin has been recommended for US Food and Drug Administration (FDA) approval for cSSSI [4] and currently is also being investigated for nosocomial pneumonia. Unfortunately, at the same time, several other pre-registration candidates - oritavancin, ceftobiprole, and iclaprim - have not yet received the same recommendation.

These new antibiotics emerged against a backdrop of reduced activity in the area of antibiotic discovery. Only five new antibiotics were approved from 2003 to 2007, compared with 16 in the period from 1983 to 1987 [1]. It is perhaps not surprising that there are a number of weak points in the current range of available antibiotics for the treatment Gram-positive infections, due to limitations in either efficacy or tolerability. Such therapeutic gaps include enterococcal bloodstream infections [5], oral drugs for infections due to community-acquired MRSA [6], and efficacy of treatment for invasive infections of critically ill patients [7].
The situation for the treatment of Gram-negative infections is even bleaker [8]. The reason for the especially slow introduction of new compounds may be in the inherent difficulties in discovering anti-Gram-negative agents. The impermeable nature of the Gram-negative envelope and presence of multiple efflux pumps in combination with other resistance mechanisms conspire to increase the difficulty of this task [9].

A few licensed antibiotics do hold some promise as Gram-negative therapies. Doripenem is a new-generation carbapenem that has demonstrated clinical efficacy against *P. aeruginosa* in investigational trials, and tigecycline is currently under investigation for *A. baumannii* infection [8]. Additionally, ceftobiprole could potentially become comparable to the intravenous cephalosporins (for example, ceftazidime) as a therapy against *P. aeruginosa* infection. However, it will be some years before the clinical efficacy of these agents in the face of existing and evolving resistance mechanisms is understood.

**Future antibiotics**

If the rise and spread of antibiotic resistance continue to follow the same worrying trend, it is reasonable to assume that resistance to the newer antibiotics will emerge. Reduced susceptibility to linezolid [10] and daptomycin [11] has already been encountered in the clinical setting. Given that (even despite prudent usage) the life span of a new antibiotic will be limited by emerging resistance, it is vital to have a continuous pipeline of new antibiotics in place that are not affected by existing resistance mechanisms. A number of antibiotics that are currently in development to reach the market in 2011 to 2013 are listed in Table 1.

It is striking that all of the listed development compounds belong to established antibiotic classes to which resistance is already prevalent among key pathogens. These nevertheless may offer advantages over their predecessors in terms of safety, tolerability, pharmacokinetics (dosing), and antibacterial spectrum or improvements in potency with the potential to overcome at least some of the resistance problems originally attributed to that class. By way of example, there appears to be renewed interest in new quinolone antibiotics. The approaches involved vary and include testing of more potent quinolones to overcome resistance (for example, delafloxacin and nemonoxacin) or investigating more specialised indications (for example, finafloxacin for *Helicobacter pylori* eradication and WCK771 as an intravenous MRSA active quinolone).

Also of note is that there are no new agents in development for tuberculosis (TB). Current investigations into new treatments are focused on using antibiotics of existing classes that have not yet been used against TB. Fluoroquinolones and linezolid are two such examples [12]. Whether these options will provide a long-term solution for XDR TB is uncertain and clearly much more needs to be done to prevent this disease becoming untreatable.

**Future directions**

The current shortage of effective antibiotics and the lack of novel agents in development imply that future treatment strategies for resistant bacteria may have to

---

**Table 1. Development pipeline for antibiotics in phase II clinical trials and beyond**

| Product          | Class       | Main segment | Status   | Indication          |
|------------------|-------------|--------------|----------|---------------------|
| Delafloxacin     | Quinolone   | Hospital     | Phase II | CAP, SSSI           |
| Nemonoxacin      | Quinolone   | Community    | Phase II | CAP, DFI            |
| WCK 771          | Quinolone   | Hospital     | Phase II | SSSI                |
| Finafloxacin     | Quinolone   | Specialised indication | Phase II | *Helicobacter pylori*, UTI |
| PZ-601           | β-lactam    | Hospital     | Phase II | SSSI                |
| NXL 104/ceftazidime | β-lactam inhibitor | Hospital | Phase II | cUTI, cIAI          |
| Cefaroline       | β-lactam    | Hospital     | Phase III| CAP, SSSI           |
| Oritavancin      | Glycopeptide| Hospital     | Phase III| SSSI                |
| Dalbavancin      | Glycopeptide| Hospital     | Phase III| SSSI, CR-BSI        |
| Telavancin       | Glycopeptide| Hospital     | Phase III| SSSI, HAP           |
| PTK0796          | Glycylcycline| Hospital    | Phase III| CAP, SSSI           |
| Iclaprim         | Trimethoprim| Hospital     | Phase III| SSSI, HAP           |
| Torezolid        | Oxazolidinone| Hospital   | Phase II | SSSI                |
| Radezolid        | Oxazolidinone| Hospital    | Phase II | CAP, SSSI           |
| Cethromycin      | Macro-/ketolide| Community | Phase III| CAP                 |
| NXL 103          | Streptogramin| Community | Phase II | SSSI, CAP           |

CAP, community-acquired pneumonia; cIAI, complicated intra-abdominal infection; CR-BSI, catheter-related bloodstream infection; cUTI, complicated urinary tract infection; DFI, diabetic foot infection; HAP, hospital-acquired pneumonia; SSSI, skin and skin structure infection; UTI, urinary tract infection.
rely on therapeutic approaches that disable existing resistance mechanisms. Inhibitors of extended-spectrum β-lactamases (ESBLs) could improve the life span of existing or new β-lactams; one such example is ESBL inhibitor NXL 104, which is currently under investigation in combination with ceftazidime [12] and in the future will be investigated in combination with cefepime [13]. Another interesting approach has been taken by Mpex Pharmaceuticals (San Diego, CA, USA), whose efflux pump inhibitor technology could one day offer a substantial improvement to the treatment of Gram-negative infections [14].

Despite the relatively recent introduction of two new antibacterial classes, the current range of treatment options for infections caused by antibiotic-resistant bacteria is far from adequate. Most of the recent advances have been for infections caused by Gram-positive bacteria; however, there are still large gaps in the therapeutic scope of these new drugs. Neglect in the areas of Gram-negative and TB antibacterial discovery has opened a potential window in which certain infections may become untreatable before new drugs become available.

It is clear that antibiotic resistance will continue to emerge and spread and that sustained research efforts to identify and develop new therapeutic options are required in order just to keep pace with the bacteria. The situation we face with resistance today and, more importantly, in the future will be manageable only with considerable efforts from the research community, pharmaceutical industry, and regulatory bodies, to improve the productivity of new antibiotics and treatment options for resistant bacteria.

**Abbreviations**
cSSSI, complicated skin and skin structure infection; ESBL, extended-spectrum β-lactamase; FDA, Food and Drug Administration; MRSA, methicillin-resistant *Staphylococcus aureus*; TB, tuberculosis; VRE, vancomycin-resistant enterococci; XDR, extensively drug-resistant.

**Competing interests**
WS is an employee of MerLion Pharmaceuticals Pte Ltd (Singapore); HL is an employee of MerLion Pharmaceuticals GmbH (Berlin, Germany) and holds stock options in MerLion Pharmaceuticals Pte Ltd (Singapore).

**References**

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE Jr, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: *Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America*. Clin Infect Dis 2009, 48:1-12.

2. Stryjewski ME, Chambers HF: *Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus*. Clin Infect Dis 2008, 46(Suppl 5):S368-77.

3. Jassal M, Bishai WR: *Extensively drug-resistant tuberculosis*. Lancet Infect Dis 2009, 9:19-30.

4. Theravance receives complete response letter on the telavancin new drug application for the treatment of cSSSI [press release]. South San Francisco, CA, USA: Theravance; 2009.

5. Arias CA, Murray BE: *Emergence and management of drug-resistant enterococcal infections*. Expert Rev Anti Infect Ther 2008, 6:637-55.

6. Moellering RC Jr: *Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection*. Clin Infect Dis 2008, 46:1032-7.

7. Schmidt-Ioanas M, de Roux A, Lode H: *New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient*. Curr Opin Crit Care 2005, 11:481-6.

8. Talbot GH: *What is in the pipeline for Gram-negative pathogens?* Expert Rev Anti Infect Ther 2008, 6:39-49.

9. Nikaido H: *Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria*. Semin Cell Dev Biol 2001, 12:215-23.

10. Seedat J, Zick G, Klare I, Konstabel C, Weiler N, Sahly H: *Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection*. Antimicrob Agents Chemother 2006, 50:4217-9.

11. Teske JR, Sinner SW, Segal RE, Huang V, Alexandre SS, McGowan JE Jr, Weinstein MP: *Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy*. Int J Antimicrob Agents 2009, 33:564-8.

12. ClinicalTrials.gov homepage [http://www.clinicaltrials.gov].

13. Novexel and Forest Laboratories announce license agreement for NXL 104, a novel broad-spectrum beta lactamase inhibitor [press release]. New York, NY, USA: Forrest Laboratories Inc; 2008.

14. GlaxoSmithKline and Mpex Pharmaceuticals form alliance to develop novel efflux pump inhibitors for use against serious Gram-negative infections [press release]. San Diego, CA, USA: Mpex Pharmaceuticals; 2008.